A new approach to combretastatin D2.
David Cousin1, John Mann, Mark Nieuwenhuyzen
1School of Chemistry, Queen's University Belfast, Stranmillis Rd., Belfast, UK BT9 5AG.
Organic & Biomolecular Chemistry
|December 17, 2005
Summary
Researchers developed a quick and efficient synthesis for combretastatin D2. Preliminary biological results are also presented, offering insights into its potential applications.
Area of Science:
- Organic Chemistry
- Medicinal Chemistry
Background:
- Combretastatin D2 is a natural product with potential anti-cancer properties.
- Efficient synthesis of complex molecules is crucial for drug discovery.
Purpose of the Study:
- To develop a concise and convergent synthetic route to combretastatin D2.
- To evaluate preliminary biological activity of the synthesized combretastatin D2.
Main Methods:
- A novel synthetic strategy was employed to construct the combretastatin D2 core structure.
- Purification and characterization of the final product were performed using standard techniques.
- Preliminary biological assays were conducted to assess activity.
Main Results:
- A high-yielding and convergent synthesis of combretastatin D2 was achieved.
- The synthesized compound was characterized and confirmed to be combretastatin D2.
- Initial biological data indicates potential therapeutic relevance.
Conclusions:
- The developed synthetic route provides efficient access to combretastatin D2.
- This work facilitates further investigation into the biological properties and therapeutic potential of combretastatin D2.
More Related Videos
Related Concept Videos
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


